A trendof 3.9-fold lower levels for TNC+/CD9+ EVs inRTK-I glioblastoma patients was also observed when compared with themesenchymal (MES) subtype (p < 0.08) (Figure 3H). This evidence concerns the gene CD9 and glioblastoma.